Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients

Pharmacotherapy

Volumn 27, Issue 4, 2007, Pages 519-525

  Taylor, Lisa M ^a   Farzam, Farjam ^c   Cook, Aaron M ^b   Lewis, Daniel A ^b   Baumann, Robert J ^c   Kuhn, Robert J ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b University of Kentucky   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Childhood epilepsy; Continuous intravenous infusion; Migraine; Valproic acid; VPA

Indexed keywords

VALPROIC ACID;

ADOLESCENT; BENIGN CHILDHOOD EPILEPSY; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; DIAGNOSTIC VALUE; DOSE TIME EFFECT RELATION; DRUG SAFETY; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MIGRAINE; RETROSPECTIVE STUDY; REVIEW; SEIZURE;

ADMINISTRATION, ORAL; ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; FRUCTOSE; HALLUCINATIONS; HUMANS; HYPERAMMONEMIA; INFUSIONS, INTRAVENOUS; MALE; MEDICAL RECORDS; METABOLIC CLEARANCE RATE; MIGRAINE DISORDERS; PHENOBARBITAL; PHENYTOIN; RETROSPECTIVE STUDIES; SEIZURES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 34047213992     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.4.519     Document Type: Review

References (24)

1. Abbott Laboratories. Depacon (valproate sodium) package insert. North Chicago, IL; 2003.
2. Hitiris N, Brodie MJ. Evidence-based treatment of idiopathic generalized epilepsies with older antiepileptic drugs. Epilepsia 2005;46(suppl 9):149-53.
3. Wheless JW. Acute management of seizures in the syndromes of idiopathic generalized epilepsies. Epilepsia 2003;44(suppl 2):22-6.
4. Hodges BM, Mazur JE. Intravenous valproate in status epilepticus. Ann Pharmacother 2001;35:1465-70.
5. Hovinga CA, Chicella MF, Rose DF, Eades SK, Dalton JT, Phelps SJ. Use of intravenous valproate in three pediatric patients with nonconvulsive or convulsive status epilepticus. Ann Pharmacother 1999;33:579-84.
6. Uberall MA, Trollmann R, Wunsiedler U, Wenzel D. Intravenous valproate in pediatric epilepsy patients with refractory status epilepticus. Neurology 2000;54;2188-9.
7. Yu KT, Mills S, Thompson N, Cunanan C. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia 2003;44(5):724-6.
8. Peters CN, Pohlmann-Eden B. Intravenous valproate as an innovative therapy in seizure emergency situations including status epilepticus: experience in 102 adult patients. Seizure 2005;14:164-9.
9. Yamamoto LG, Yim G. The role of intravenous valproic acid in status epilepticus. Pediatric Emerg Care 2000;16(4):296-8.
10. Stillman MJ, Zajac D, Rybicki LA. Treatment of primary headache disorders with intravenous valproate: Initial outpatient experience. Headache 2004;44:65-9.
11. Cloyd JC, Fischer JH, Kriel RL, Kraus DM. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance. Clin Pharmacol Ther 1993;53:22-9.
12. Sanchez-Alcaraz A, Quintana MB, Lopez E, Rodriguez I. Valproic acid clearance in children with epilepsy. J Clin Pharm Ther 1998;23:31-4.
13. Cloyd JC, Kriel RL, Fischer JH, Sawchuk RJ, Eggerth RM. Pharmacokinetics of valproic acid in children. I. Multiple antiepileptic drug therapy. Neurology 1983;33:185-91.
14. Schobben F, Kleijh E, Vree TB. Therapeutic monitoring of valproic acid. Ther Drug Monit 1980;2(1):61-71.
15. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. Plasma concentrations of sodium valproate: their clinical value. Ann Neurol 1983;14:38-42.
16. Chadwick DW. Concentration-effect relationships of valproic acid. Clin Pharmacokinetics 1985;10:155-63.
17. Lundberg B, Nergardh A, Boreus LO. Plasma concentrations of valproate during maintenance therapy in epileptic children. J Neurol 1982;228:133-41.
18. Sankar R. Initial treatment of epilepsy with antiepileptic drugs. Neurology 2004;63(suppl 4)S30-9.
19. Cloyd JC, Kriel RL, Jones-Saete CM, Ong BY, Jancik JT, Remmel RP. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J Pediatr 1992;120:634-8.
20. Smith MC, Centorrino F, Welge JA, Collins MA. Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials. Epilepsy Behav 2004;5:746-51.
21. Dutta S, Zhang Y. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation. Biopharm Drug Dispos 2004;25:345-52.
22. Bauer LA. Applied clinical pharmacokinetics. New York: McGraw-Hill; 2001:516-49.
23. Beydoun A, Sackellares JC, Shu V. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote monotherapy for partial seizures study group. Neurology 1997;48:182-8.
24. Venkataraman V, Wheless JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res 1999;35:147-53.